Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | 2.14%300.1M | 77.96%111.4M | -37.67%65.2M | 58.93%82.8M | -45.37%40.7M | 85.01%293.8M | 769.44%62.6M | 252.19%104.6M | 23.75%52.1M | -6.64%74.5M |
Net income from continuing operations | -90.76%12.5M | -199.79%-46.6M | -78.45%6.4M | -50.78%28.4M | 1,925.00%24.3M | 55.52%135.3M | 100.43%46.7M | 430.36%29.7M | 277.12%57.7M | -97.20%1.2M |
Operating gains losses | 57.76%43.7M | -26.64%16.8M | 279.49%14.8M | 202.13%9.6M | -75.73%2.5M | 14.46%27.7M | 6.51%22.9M | 85.71%3.9M | -687.50%-9.4M | 1,130.00%10.3M |
Depreciation and amortization | 29.21%152.6M | 9.00%33.9M | 73.70%50.2M | 42.62%34.8M | 0.00%33.7M | 2.87%118.1M | 5.07%31.1M | -3.02%28.9M | -12.86%24.4M | 22.99%33.7M |
Deferred tax | 7,835.29%131.5M | 1,231.87%121.2M | 285.71%2.7M | 152.58%5.1M | 238.89%2.5M | -107.76%-1.7M | -4.21%9.1M | -90.67%700K | -348.72%-9.7M | -280.00%-1.8M |
Other non cash items | -23.05%45.4M | -18.57%11.4M | -19.74%12.2M | -20.98%11.3M | -32.26%10.5M | 1,234.62%59M | 418.52%14M | 442.86%15.2M | 293.24%14.3M | 569.70%15.5M |
Change In working capital | -90.85%-118.9M | 52.05%-31.5M | -229.36%-28.2M | 27.85%-21.5M | -430.70%-37.7M | 39.10%-62.3M | 22.52%-65.7M | 194.37%21.8M | -727.78%-29.8M | 23.91%11.4M |
-Change in receivables | -52.75%-72.1M | -41.03%-40.9M | -45.80%-19.1M | -25.90%-17.5M | -38.64%5.4M | -33.71%-47.2M | 25.06%-29M | -555.00%-13.1M | -508.82%-13.9M | 340.00%8.8M |
-Change in other working capital | -209.93%-46.8M | 125.61%9.4M | -126.07%-9.1M | 74.84%-4M | -1,757.69%-43.1M | 77.46%-15.1M | 20.39%-36.7M | 265.40%34.9M | -127.14%-15.9M | -63.89%2.6M |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | 2.14%300.1M | 77.96%111.4M | -37.67%65.2M | 58.93%82.8M | -45.37%40.7M | 85.01%293.8M | 769.44%62.6M | 252.19%104.6M | 23.75%52.1M | -6.64%74.5M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | -116.53%-488.5M | -92.25%-111.7M | -93.75%-49.6M | -242.84%-244.1M | -17.54%-83.1M | 26.73%-225.6M | 19.53%-58.1M | 52.85%-25.6M | 46.98%-71.2M | -50.11%-70.7M |
Net PPE purchase and sale | -39.37%-87.8M | -7.07%-21.2M | -5.21%-20.2M | -249.35%-26.9M | -19.63%-19.5M | 6.94%-63M | -102.04%-19.8M | -10.98%-19.2M | 65.63%-7.7M | 10.44%-16.3M |
Net business purchase and sale | -191.62%-375.9M | -181.55%-87M | -336.07%-26.6M | -394.47%-205.7M | -12.52%-56.6M | 43.64%-128.9M | 50.56%-30.9M | 83.51%-6.1M | 62.04%-41.6M | -156.63%-50.3M |
Net other investing changes | 26.41%-24.8M | 52.70%-3.5M | -833.33%-2.8M | 47.49%-11.5M | -70.73%-7M | -193.04%-33.7M | -7,500.00%-7.4M | ---300K | -852.17%-21.9M | 55.91%-4.1M |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | -116.53%-488.5M | -92.25%-111.7M | -93.75%-49.6M | -242.84%-244.1M | -17.54%-83.1M | 26.73%-225.6M | 19.53%-58.1M | 52.85%-25.6M | 46.98%-71.2M | -50.11%-70.7M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 268.81%262M | 207.62%48M | 64.22%-7.3M | 486.94%189.6M | 176.94%31.7M | -468.65%-155.2M | -123.10%-44.6M | 57.50%-20.4M | 17.37%-49M | 5.72%-41.2M |
Net issuance payments of debt | 2,209.74%450.4M | 1,225.00%95.4M | 93.06%33.4M | 5,086.00%249.3M | --72.3M | 103.03%19.5M | 101.17%7.2M | 284.04%17.3M | 68.35%-5M | --0 |
Net common stock issuance | --0 | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
Net other financing activities | -7.84%-188.4M | 8.49%-47.4M | -7.96%-40.7M | -35.68%-59.7M | 1.46%-40.6M | 11.14%-174.7M | 31.75%-51.8M | 2.33%-37.7M | -1.15%-44M | -6.74%-41.2M |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | 268.81%262M | 207.62%48M | 64.22%-7.3M | 486.94%189.6M | 176.94%31.7M | -468.65%-155.2M | -123.10%-44.6M | 57.50%-20.4M | 17.37%-49M | 5.72%-41.2M |
Net cash flow | ||||||||||
Beginning cash position | -30.75%195.9M | -6.02%221.8M | 20.35%213.5M | -24.56%185.2M | -30.75%195.9M | -27.44%282.9M | 52.45%236M | -21.99%177.4M | -35.21%245.5M | -27.44%282.9M |
Current changes in cash | 184.60%73.6M | 218.95%47.7M | -85.84%8.3M | 141.56%28.3M | 71.39%-10.7M | 18.69%-87M | -131.30%-40.1M | 180.72%58.6M | 55.05%-68.1M | -240.00%-37.4M |
End cash Position | 37.57%269.5M | 37.57%269.5M | -6.02%221.8M | 20.35%213.5M | -24.56%185.2M | -30.75%195.9M | -30.75%195.9M | 52.45%236M | -21.99%177.4M | -35.21%245.5M |
Free cash flow | 2.29%209.7M | 108.18%89.1M | -47.49%45M | 112.55%55.9M | -60.76%19.7M | 162.15%205M | 376.13%42.8M | 591.13%85.7M | 33.50%26.3M | -18.51%50.2M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |